Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
Key facts
- Who runs it
- The First Affiliated Hospital of Soochow University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 200 people enrolled
- Started
- 1 Apr 2023
- Ended
- 10 Jan 2025
- Type of study
- Observational
- Treatments tested
- Letermovir
- Record updated
- 19 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Haplo-SCT candidate (adult) who has decided to primary transplant and is willing to participate in the study
- The haplo-SCT candidate (adult) should be CMV seropositive recipients
Who cannot take part
- CMV-seronegative patient receiving a negative CMV donor graft
- Patients having active CMV DNAemia at the time of letermovir initiation
- Patient having signed the informed consent but not grafted
- Patient recruited in a clinical study on an anti-CMV trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In the 30 years of fighting CMV infection, the mortality rate among HSCT patients has significantly reduced. Now, the focus is on improving the prognosis of HSCT patients and preventing CMV infection. The emergence of letermovir has provided a new opportunity in this regard. Letermovir, the only drug approved for CMV infection prevention in HSCT patients, works by inhibiting the CMV DNA terminase complex. Phase III studies have shown that letermovir significantly reduces CMV infection and all-cause mortality after HSCT, without increasing myelosuppression or nephrotoxicity. Real-world studies have further confirmed its efficacy in reducing CMV infection rates and antiviral use. Letermovir's global success has not yet been fully realized in China, where it is still in its early stages of use.
The group in the trial
- 200 haplo-HSCT recipients who are CMV seropositive
The study consists 200 cases CMV-R+ adult (\>18 years) recipients of haplo-HCT. All patients will receive letermovir prophylaxis. Consider a simple interim analysis of the experimental group could be arranged after 150 patients are enrolled if necessary. Supportive care is provided by institutional standards of care (e.g., acyclovir for herpes simplex virus and varicella zoster virus prevention). Letermovir prophylaxis is started on day 0 or no longer than 28 days after transplantation. During the study period, letermovir 480 mg PO/IV once daily (or 240 mg per day in patients taking cyclosporine) was administered from day 0 to day +100 post-HCT. CMV monitoring and preemptive therapy were performed according to local protocol. Plasma CMV viral load (VL) is monitored by quantitative CMV PCR, starting on day +7 and continued weekly until week 6, then every 2-4 weeks for months until week 24.
Treatment: Letermovir
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Letermovir Prophylaxis for Cytomegalovirus Infection in Haploidentical Allogeneic Hematopoietic Cell Transplant Recipients: Single-center Real-world Data in China
- Publications
- Letermovir for CMV prophylaxis after haploidentical HSCT: A prospective study of direct and indirect effects.International journal of antimicrobial agents, 2026
- Record updated
- 19 February 2025